Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Payables (2023 - 2025)

Beta Bionics' Payables history spans 3 years, with the latest figure at $5.0 million for Q4 2025.

  • For Q4 2025, Payables rose 75.25% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $5.0 million, up 75.25%, while the annual FY2025 figure was $5.0 million, 75.25% up from the prior year.
  • Payables for Q4 2025 was $5.0 million at Beta Bionics, up from $4.5 million in the prior quarter.
  • Across five years, Payables topped out at $5.0 million in Q4 2025 and bottomed at $1.2 million in Q4 2023.
  • The 3-year median for Payables is $3.4 million (2025), against an average of $3.4 million.
  • The largest annual shift saw Payables surged 144.6% in 2024 before it skyrocketed 75.25% in 2025.
  • A 3-year view of Payables shows it stood at $1.2 million in 2023, then surged by 144.6% to $2.9 million in 2024, then soared by 75.25% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for BBNX's Payables are $5.0 million (Q4 2025), $4.5 million (Q3 2025), and $3.4 million (Q2 2025).